← boardnext 2029-02
ATNM
Actinium Pharmaceuticalsdistress 3/10 · well-funded / low risk$0.900%today-52% from 52w high
Lead: Acute Myeloid Leukemia · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$42M
Runway
1.8 yrs
Shares 1y
+1%
Price & events
-32.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.1%
1D
+1.0%
1W
-11.8%
1M
-31.4%
3M
-30.8%
6M
-51.9%
1Y
-88.8%
2Y
-87.3%
5Y
-88.6%
All
Overview
- Market Cap
- $28.22M
- Volume
- 3.60K
- 52 Week Range
- $0.88 – $1.87
- Total Shares
- 31.37M
- Float Shares
- 31.19M
- Short %
- 3.00%
- % Held by Insiders
- 2.35%
- % Held by Institutions
- 20.61%
- RVOL
- 0.03x
- Beta
- -0.01
Pipeline stages · 1 programs
131I-apamistamab, Fludarabine, Cyclophosphamide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2029-02 Estimated 50% readout ~2029-04-17 | Phase 2/3 | 131I-apamistamab, Fludarabine, Cyclophosphamide | Acute Leukemia, Myeloid Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Myelogenous Leukemia, Myelogenous Leukemia, Acute, Myelogenous Leukemia in Relapse, Transplant-Related Disorder, Allogeneic Disease, Refractory AML | — | not yet recruiting |
Catalyst news & presentations · 2
- May 30-June 2, 2026conferencedata presentationsecondaryATNM-400 · Preclinical data on ATNM-400 in prostate and NSCLC models, and chelator optimization.SEC 8-K
- 2026-05-27warning letterReceived NYSE American notice of non-compliance with continued listing standards due to stockholders' equity below $4M and net losses.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-03-31Stephens & Co.Overweight
- 2025-06-24HC Wainwright & Co.Buy
- 2025-05-12HC Wainwright & Co.Buy
- 2025-04-28HC Wainwright & Co.Buy
- 2025-04-01HC Wainwright & Co.Buy
- 2025-03-27HC Wainwright & Co.Buy
Competitors — Acute Myeloid Leukemia
- ABBVAbbVie Inc.$451.1B · D2
- SLSSELLAS Life Sciences Group, Inc.$2.2B · D4
- SNDXSyndax Pharmaceuticals Inc$1.9B · D5
- KURAKura Oncology, Inc.$917M · D5
- FHTXFoghorn Therapeutics Inc.$303M · D4
- DTILPRECISION BIOSCIENCES INC$185M · D6
- BMEABiomea Fusion, Inc.$90M · D6
- INABIN8BIO, INC.$12M · D7
- MBRXMoleculin Biotech, Inc.$11M · D8
- BPTHBIO-PATH HOLDINGS, INC.$2M · D9
Recent news
- 2026-07-22Actinium Pharmaceuticals (ATNM) Q3 2025 earnings summary - Quartr
- 2026-07-22Actinium Pharmaceuticals (ATNM) Life Sciences Investor Forum Summary - Quartr
- 2026-07-16Actinium Pharmaceuticals (ATNM) Dips 2.9% as Biotech Stock Nears Support Zone - VWAP Breakout - dars.gov.et
- 2026-07-15Actinium Pharmaceuticals (ATNM) Gains 2.77% as Stock Tests Key Resistance Near $0.97 - Jelly Roll Trade - dars.gov.et
- 2026-07-10Actinium Pharmaceuticals (ATNM) Q3 2025 earnings summary - Quartr
- 2026-07-10ATNM Should I Buy - Intellectia AI
- 2026-07-08Actinium Pharmaceuticals (ATNM) Q4 2025 earnings summary - Quartr
- 2026-06-27ATNM Stockholders Have Opportunity to Lead Actinium Pharmaceutica - The National Law Review
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.